381 related articles for article (PubMed ID: 24313946)
1. Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients.
Dzieżyc K; Karliński M; Litwin T; Członkowska A
Eur J Neurol; 2014 Feb; 21(2):332-7. PubMed ID: 24313946
[TBL] [Abstract][Full Text] [Related]
2. D-penicillamine versus zinc sulfate as first-line therapy for Wilson's disease.
Członkowska A; Litwin T; Karliński M; Dziezyc K; Chabik G; Czerska M
Eur J Neurol; 2014 Apr; 21(4):599-606. PubMed ID: 24447648
[TBL] [Abstract][Full Text] [Related]
3. Maintenance zinc therapy after initial penicillamine chelation to treat symptomatic hepatic Wilson's disease in resource constrained setting.
Gupta P; Choksi M; Goel A; Zachariah U; Sajith KG; Ramachandran J; Chandy G; Kurian G; Rebekah G; Eapen CE
Indian J Gastroenterol; 2018 Jan; 37(1):31-38. PubMed ID: 29457214
[TBL] [Abstract][Full Text] [Related]
4. Effect of penicillamine and zinc on iron metabolism in Wilson's disease.
Medici V; Di Leo V; Lamboglia F; Bowlus CL; Tseng SC; D'Incà R; Irato P; Burra P; Martines D; Sturniolo GC
Scand J Gastroenterol; 2007 Dec; 42(12):1495-500. PubMed ID: 17994470
[TBL] [Abstract][Full Text] [Related]
5. Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
Sinha S; Taly AB
J Neurol Sci; 2008 Jan; 264(1-2):129-32. PubMed ID: 17765927
[TBL] [Abstract][Full Text] [Related]
6. A clinical study of Wilson's disease: The experience of a single Egyptian Paediatric Hepatology Unit.
El-Karaksy H; Fahmy M; El-Raziky MS; El-Hawary M; El-Sayed R; El-Koofy N; El-Mougy F; El-Hennawy A; El-Shabrawi M
Arab J Gastroenterol; 2011 Sep; 12(3):125-30. PubMed ID: 22055589
[TBL] [Abstract][Full Text] [Related]
7. The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease.
Walshe JM
QJM; 2011 Sep; 104(9):775-8. PubMed ID: 21622540
[TBL] [Abstract][Full Text] [Related]
8. Symptomatic copper deficiency in three Wilson's disease patients treated with zinc sulphate.
Dzieżyc K; Litwin T; Sobańska A; Członkowska A
Neurol Neurochir Pol; 2014; 48(3):214-8. PubMed ID: 24981187
[TBL] [Abstract][Full Text] [Related]
9. Histologic evolution and long-term outcome of Wilson's disease: results of a single-center experience.
Sini M; Sorbello O; Sanna F; Battolu F; Civolani A; Fanni D; Faa G; Demelia L
Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):111-7. PubMed ID: 23011036
[TBL] [Abstract][Full Text] [Related]
10. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
[TBL] [Abstract][Full Text] [Related]
11. Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease.
Farinati F; Cardin R; D'inca R; Naccarato R; Sturniolo GC
J Lab Clin Med; 2003 Jun; 141(6):372-7. PubMed ID: 12819634
[TBL] [Abstract][Full Text] [Related]
12. Dominant psychiatric manifestations in Wilson's disease: a diagnostic and therapeutic challenge!
Srinivas K; Sinha S; Taly AB; Prashanth LK; Arunodaya GR; Janardhana Reddy YC; Khanna S
J Neurol Sci; 2008 Mar; 266(1-2):104-8. PubMed ID: 17904160
[TBL] [Abstract][Full Text] [Related]
13. Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine.
Lowette KF; Desmet K; Witters P; Laleman W; Verslype C; Nevens F; Fevery J; Cassiman DM
Eur J Gastroenterol Hepatol; 2010 May; 22(5):564-71. PubMed ID: 20042865
[TBL] [Abstract][Full Text] [Related]
14. Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilson's disease.
Dzieżyc K; Litwin T; Chabik G; Członkowska A
Funct Neurol; 2015; 30(4):264-8. PubMed ID: 26727705
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
[TBL] [Abstract][Full Text] [Related]
16. Syndromic variability of Wilson's disease in children. Clinical study of 44 cases.
Giacchino R; Marazzi MG; Barabino A; Fasce L; Ciravegna B; Famularo L; Boni L; Callea F
Ital J Gastroenterol Hepatol; 1997 Apr; 29(2):155-61. PubMed ID: 9646197
[TBL] [Abstract][Full Text] [Related]
17. Wilson's disease-cause of mortality in 164 patients during 1992-2003 observation period.
Członkowska A; Tarnacka B; Litwin T; Gajda J; Rodo M
J Neurol; 2005 Jun; 252(6):698-703. PubMed ID: 15742108
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate.
Czlonkowska A; Gajda J; Rodo M
J Neurol; 1996 Mar; 243(3):269-73. PubMed ID: 8936358
[TBL] [Abstract][Full Text] [Related]
19. [Acute recurrent hemolytic anemia as the first manifestation of Wilson's disease: Report of a case].
El Khattabi A; Seddik H; Fatihi J; Salaheddine H; Badaoui M; Amézyane T; Mahassine F; Ohayon V
Transfus Clin Biol; 2009 Mar; 16(1):39-42. PubMed ID: 19329346
[TBL] [Abstract][Full Text] [Related]
20. [Pathogenesis and treatment of Wilson's disease].
Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
